PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -43.99M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-43.99M | (m) |
| 2026-03-31 | (m) | $-151.18M | (m) |
| 2025-12-31 | (m) | $-244.09M | (m) |
| 2025-09-30 | (m) | $-280.46M | (m) |
| 2025-06-30 | (m) | $-302.92M | (m) |
| 2025-03-31 | (m) | $-110.27M | (m) |
| 2024-12-31 | (m) | $-122.31M | (m) |
| 2024-09-30 | (m) | $-131.83M | (m) |
| 2024-06-30 | (m) | $-50.92M | (m) |
| 2024-03-31 | (m) | $-172.40M | (m) |
| 2023-12-31 | (m) | $-147.03M | (m) |
| 2023-09-30 | (m) | $-73.20M | (m) |
| 2023-06-30 | (m) | $-140.87M | (m) |
| 2023-03-31 | (m) | $-127.52M | (m) |
| 2022-12-31 | (m) | $-116.95M | (m) |
| 2022-09-30 | (m) | $-156.48M | (m) |
| 2022-06-30 | (m) | $-1.47M | (m) |
| 2022-03-31 | (m) | $67.42M | (m) |
| 2021-12-31 | (m) | $66.97M | (m) |
| 2021-09-30 | (m) | $69.44M | (m) |
| 2021-06-30 | (m) | $-70.39M | (m) |
| 2021-03-31 | (m) | $-124.31M | (m) |
| 2020-12-31 | (m) | $-111.14M | (m) |
| 2020-09-30 | (m) | $-101.98M | (m) |
| 2020-06-30 | (m) | $-90.85M | (m) |
| 2020-03-31 | (m) | $-80.38M | (m) |
| 2019-12-31 | (m) | $-77.68M | (m) |
| 2019-09-30 | (m) | $-78.58M | (m) |
| 2019-06-30 | (m) | $-83.69M | (m) |
| 2019-03-31 | (m) | $-127.77M | (m) |
| 2018-12-31 | (m) | $-155.65M | (m) |
| 2018-09-30 | (m) | $-180.94M | (m) |
| 2018-06-30 | (m) | $-208.78M | (m) |
| 2018-03-31 | (m) | $-166.60M | (m) |
| 2017-12-31 | (m) | $-153.24M | (m) |
| 2017-09-30 | (m) | $-154.38M | (m) |
| 2017-06-30 | (m) | $-145.23M | (m) |
| 2017-03-31 | (m) | $-167.97M | (m) |
| 2016-12-31 | (m) | $-160.11M | (m) |
| 2016-09-30 | (m) | $-135.36M | (m) |
| 2016-06-30 | (m) | $-115.10M | (m) |
| 2016-03-31 | (m) | $-92.93M | (m) |
| 2015-12-31 | (m) | $-80.61M | (m) |
| 2015-09-30 | (m) | $-69.56M | (m) |
| 2015-06-30 | (m) | $-59.77M | (m) |
| 2015-03-31 | (m) | $-40.20M | (m) |
| 2014-12-31 | (m) | $-7.15M | (m) |
| 2014-09-30 | (m) | $-5.09M | (m) |
| 2014-06-30 | (m) | $-1.60M | (m) |
| 2014-03-31 | (m) | $-14.19M | (m) |
| 2013-12-31 | (m) | $-41.00M | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
| 2012-12-31 | (m) | $-41.41M | (m) |
| 2012-09-30 | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) |
| 2011-12-31 | (m) | $-29.67M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |